ES PHARMA
ActiveFrom the official registers: KBO 2 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
ES PHARMA has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €46,820 and a net result of €32,777. Its solvency ranks better than 69% of 22,726 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
History
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
03-06
financial year 2025 · micro format
2025
31-12
Financial
Liquidity more than doubledcurrent ratio 3.09
The current ratio rises from 1.43 to 3.09.
02-06
financial year 2024 · micro format
2024
07-05
Gazette deed
IncorporationAppointment: SMET Emma Olga Simonna (director) · Founder · Capital9 points ▸
Gazette deed
Incorporation
Appointment: SMET Emma Olga Simonna (director) · Founder · Capital9 points ▸
- Incorporation, “ES PHARMA” (deed in Dutch)
- Founder, SMET Emma Olga Simonna
- Capital
- Registered office clause, “2400 Mol,Zandputlaan 38, oprichter” (deed in Dutch)
- Pre-incorporation commitments, “takeover, alle verbintenissen en verplichtingen die eruit voortvloeien en alle activiteiten ondernomen in naam en voor rekening van vennootschap in oprichting” (deed in Dutch)
- Board rule, 1, “vergadering” (deed in Dutch)
- Director appointment, SMET Emma Olga Simonna (director (not named in the articles))
- Other provision, “verklaring geen beroepsverbod, geen beroepsverbod uitgesproken” (deed in Dutch)
- Founding capital
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank